Key Highlights

● Total revenues were $928.0 million, up 18% from $789.1 million.

● Operating income rose 40% to $275.0 million.

● More than 180 customers are live on Vault CRM, including five top 20 biopharmas.

● Third-quarter revenue is guided at $932 million to $935 million.

Veeva Systems Inc. (NYSE:VEEV) has become a test case for whether specialist industry software can add artificial intelligence products without disturbing its core economics. Its second-quarter results for fiscal 2027, announced on August 26, 2026, showed total revenues up 18% and a higher operating profit. Management attributed its momentum to customer commitments to Vault CRM and to early development of AI agent products.

Business and sector

Veeva provides cloud software to the global life sciences industry, from pharmaceutical groups to emerging biotechnology companies, and says it serves more than 1,500 customers. Its products cover commercial functions such as customer relationship management, as well as clinical, regulatory, safety and quality processes. It is a public benefit corporation, which means its governance requires a balance between the interests of shareholders, customers, employees and the industries it serves. Demand therefore depends heavily on drug-industry budgets and regulation.

The reported figures

For the quarter ended July 31, 2026, total revenues were $928.0 million, up from $789.1 million a year earlier, an 18% increase. Subscription revenues were $766.8 million, up 16% from $659.2 million. Operating income was $275.0 million, up 40% from $195.9 million, and non-GAAP operating income was $415.9 million, up 18%.

Net income was $273.4 million against $200.3 million, up 37%, and fully diluted earnings per share were $1.66 against $1.19. On a non-GAAP basis, which adjusts for items such as stock-based compensation, earnings per share were $2.35 against $1.99. The chief financial officer said results exceeded guidance on all metrics and that the full-year view improved across the board.

Product and customer developments

The company said more than 180 customers are live on Vault CRM, including five top 20 biopharmas, and that two top 20 biopharmas and one large enterprise biopharma committed in August, taking total top 20 commitments to 12. It reported five early adopters of Veeva Falcon, an agentic platform for clinical, regulatory and safety work, with initial go-lives expected this year. Veeva also acquired Copli during the quarter, launched Falcon MLR for content review, and said Veeva Safety passed 100 customers. In quality software it added more than 30 customers, and a large enterprise biopharma chose Veeva EDC, extending an existing relationship that already included other clinical applications.

Outlook and uncertainties

For the third quarter ending October 31, 2026, Veeva guided to total revenues of $932 million to $935 million and non-GAAP operating income of $417 million to $420 million. For the year ending January 31, 2027, it expects revenues of $3,682 million to $3,687 million and non-GAAP operating income of about $1,640 million. Non-GAAP earnings per share are guided to $2.33 to $2.34 for the quarter and about $9.21 for the year. The company does not provide GAAP equivalents because items such as stock-based compensation are hard to predict.

The company's cautionary language points to risks including product performance, security and privacy, competition, customer priorities, and developments in the life sciences industry such as regulatory, funding or policy changes. It also cites macroeconomic and geopolitical events, including trade policy and currency movements. The guided third-quarter revenue is only modestly above the second-quarter figure, so investors may focus on how consistently growth is sustained.

Falcon Go-Lives and Vault CRM Conversions

Veeva's second-quarter total revenues rose 18% to $928.0 million, operating income rose 40% to $275.0 million, and more than 180 customers are live on Vault CRM, with total top 20 biopharma commitments at 12. Guidance of $932 million to $935 million of third-quarter revenue sits only modestly above the second-quarter figure.

The next report will cover the quarter ending October 31, 2026. Points to follow include conversion of Vault CRM commitments into live deployments, the first Falcon go-lives, and evidence that AI products broaden revenue rather than simply replace existing modules, while the pace of operating profit growth relative to revenue growth and any change in the guidance range, particularly full-year revenue, operating income and per-share earnings, will also be informative.